A novel method of projecting cystic fibrosis birth cohort survival estimates that overcomes short duration of follow-up  by Jackson, A. et al.
S112 11. Epidemiology/Registry
431* A novel method of projecting cystic ﬁbrosis birth cohort survival
estimates that overcomes short duration of follow-up
A. Jackson1,2, L. Daly1, C. Kelleher1, A.L. Jackson3, M. Harrington2, S. Zhou2,
L. Foley2, P. Fitzpatrick1. 1University College Dublin, School of Public Health,
Physiotherapy & Population Science, Dublin, Ireland; 2Cystic Fibrosis Registry
of Ireland (CFRI), Woodview House, Ireland; 3Trinity College Dublin, School of
Natural Science, Dept of Zoology, Dublin, Ireland
The current lifetable method, which is frequently used to estimate CF life ex-
pectancy, does not allow for changes in age-speciﬁc mortality rates over time despite
observed improvements in childhood mortality rates. Longitudinal survival analysis
of birth cohorts facilitates rate adjustment, but median survival estimates may not
be available for many years.
We aimed to improve CF survival analysis by developing a parametric modelling
technique to estimate birth cohort survival in situations where duration of follow-up
is short.
Data on births and registered deaths were sourced from the CFRI (>90% enrolment
by 2009) and the Central Statistics Ofﬁce, 1980–2007. Current lifetable estimates
were prepared using the US registry method and the Kaplan–Meier (K−M) method
was employed to calculate survival in 4 ﬁve-year birth cohorts (1980–1999). The
best ﬁtting parametric model to birth cohort data was selected.
Current lifetable estimates of annual median survival ﬂuctuated from year to year,
requiring a lengthy observation period to establish a trend of increased survival.
K−M estimates showed increased survival in successive birth cohorts, due to
greater proportions surviving the ﬁrst year of life. Gender and year of birth had
an independent effect on survival. Median survival was unknown for persons with
CF born 1985−94 and surviving the ﬁrst year of life because 85% were alive in
2007. Using a Weibull regression model, we estimated a median age at death of
39.4 years (95% CI: 31, 47.8) for this cohort.
This novel method deals effectively with survival estimation where the duration of
birth cohort follow-up is short, and the age proﬁle of decedents continues to evolve.
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The survival and morality data of CF patients depend on the severity of the
disorder, interventions by effective patient care, and patient compliance. CF patient
registries do not exist in the Arab population, so information about the survival
of Arab CF patients is largely unknown. We identiﬁed 39 CF patients (17 male,
21 female, age 1−15 yr) born between 1992 and 2009 by a complete retrospective
and prospective data collection in the North Al Bathina region of the Sultanate
of Oman. Since patients were alive at the end of the study period, we utilized
a right censored product-limit estimation for the survival and mortality analysis.
The variants of the survival probability were analyzed by Greenwood’s variance
expression. Normal like distribution was achieved by logarithmical transformation
of the survival probability. The mean survival time estimate is 10.5 years with a
normal-based approximate 95% conﬁdence interval of ±1.8 years. The median
survival time estimate of 10±1.5 years is similar to the mean survival time
estimate. Interestingly, the mean survival time estimate of female CF patients in
our cohort is signiﬁcantly lower than of the male patients (8.7 years and 13.3 years
retrospectively). This observation agrees with the know gender difference in CF
mortality. The study documents a very low life expectancy of CF patients in our
cohort. This may result from a combination of factors, e.g. genetic predisposition,
lack of multidisciplinary management, or missed early diagnosis.
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Introduction: Median survival of cystic ﬁbrosis (CF) has been steadily increasing
approaching 40 years. As a result, a signiﬁcant number of patients are over 50 years
old and have unique features in their diagnosis, presentation and clinical problems
compared to patients with classic CF. We aim to describe this population in our
clinic.
Methods: Patients over 50 years of age from 2002 to 2008 in our clinic were
included. Diagnostic characteristics, genetic data, clinical features, microbiological
features and other comorbidities were collected.
Results: There were 30 patients that met the inclusion criteria. Nineteen patients
were female (63.3%) and twenty-eight were white (93.3%). Two patients (6.7%)
received lung transplant before their 50th birthday. Average at diagnosis was
26.1±20.7 years and 16/30 (53.3%) were diagnosed in childhood or adolescence.
Only two patients (6.7%) had meconium ileus. Mean sweat chloride was 100.1mM.
Genetic testing revealed ﬁve (16.6%) patients who were DF508 homozygotes, while
the prevalence of DF508 was 40% (24/60 genes genotyped). Pseudomonas was
present in 21 (70%) patients at last follow-up. At last follow-up, mean FEV1 was
1.45 L and FVC 2.29 L, while mean BMI was 23.1. Eight (26.7%) patients had
passed away at the time of this report. Eleven (36.7%) patients had not received IV
antibiotics during the study period. Diabetes was common in this group.
Conclusions: Patients with CF reaching 50 years of age have signiﬁcant burden of
disease even though many of them are diagnosed as adults. Future registry studies
should describe further this group and its needs
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As a result of the improvement in survival of people with CF, the proportion of
“old” patients is increasing. This study aimed to describe the characteristics of
CF patients born in Brittany who survived the age of 35.
Active enquiries were done to identify patients with classical form of CF, aged of
35 y. or more who are still alive, as well as those who died after the age of 35.
Patients were recruited through the registry set up in Brittany and by contacting the
CF centres and pulmonologists of the area. Vital statute was updated through CF
centres and birth councils.
A total of 53 long-term survivors (28 males, 25 females) were registered; 47 (68.8%)
of them were still alive at the ending date (Dec 31st 2008). Mean age of alive
patients was 41.4 y. (the oldest one being 59.9 y. old) whereas that of dead patients
was 37.8 y. The spectrum of CFTR mutations differed from that classically observed
in CF; the 2789+5G>A being particularly frequent (8.5% vs. 0.6%, p< 0.0001).
As our registry enrolled alive and dead patients born in Brittany since 1970, we
were also able to estimate, using Kaplan-Meier method, the survival probability of
patients born between 1970 and 1974 ie. likely to have reached the age of 35.
That cohort included 78 patients among whom 3/4 have died so far (n = 59).
Median survival was estimated at 17.1 y. (95% CI: [10.3; 25.6]). It did not differ
between gender (p= 0.775) and was lower than in the younger generations (log-rank:
p= 0.0086).
This study conﬁrmed the genotypic speciﬁcities of long-term CF survivors and was
able to precisely assess median survival of patients born in the 1970s.
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